
Index

FIGURE INDEX.....	17
TABLE INDEX.....	21
ANNEX INDEX	23
ABBREVIATIONS	25
RESUMEN	33
ABSTRACT.....	35
INTRODUCTION	39
1 CANCER	41
1.1 CANCER BIOLOGY.....	42
2 BREAST CANCER	46
2.1 EPIDEMIOLOGY	46
2.2 CLASSIFICATION.....	49
2.2.1 <i>Morphological and histological classification</i>	49
2.2.1.1 Staging and grade	52
2.2.1.2 Histological markers.....	54
2.2.2 <i>Molecular classification</i>	55
2.2.3 <i>Molecular profiling platforms for prognosis</i>	59
2.3 BREAST CANCER TREATMENT.....	61
3 THE HER2 POSITIVE SUBTYPE	65

3.1	HER2 RECEPTOR	65
3.1.1	<i>Structure</i>	65
3.1.2	<i>Signalling</i>	68
3.2	ANTI-HER2 THERAPY.....	70
3.3	RESISTANCE TO TRASTUZUMAB.....	75
3.3.1	<i>Increased ligand expression</i>	76
3.3.2	<i>Receptor alteration</i>	77
3.3.3	<i>Constitutive HER2 pathway activation</i>	78
4	TRIPLE NEGATIVE BREAST CANCER.....	80
4.1	TNBC LEHMANN’S CLASSIFICATION.....	81
4.2	TREATMENT.....	85
5	METFORMIN	87
6	MIRNAS.....	89
7	EXOSOMES.....	94
	HYPOTHESIS AND OBJECTIVES.....	97
1	HYPOTHESIS	99
2	OBJECTIVES	101
	MATERIALS AND METHODS	103
1	CELL CULTURE	105
1.1	CELL LINES.....	105
1.2	CULTURE CONDITIONS	107
1.3	TREATMENTS	108
1.4	MICRORNA TRANSFECTION.....	108

2	FUNCTIONAL ASSAYS	111
2.1	CELL VIABILITY ASSAY	111
2.2	WOUND HEALING ASSAY	113
2.3	CELL CYCLE ANALYSIS	114
2.4	EXOSOME ISOLATION BY ULTRACENTRIFUGATION	115
2.4.1	<i>Transmission electron microscopy</i>	117
2.5	ANGIOGENESIS ASSAY	118
3	MOLECULAR ASSAYS	120
3.1	RNA EXTRACTION.....	120
3.1.1	<i>Total RNA extraction</i>	120
3.1.2	<i>microRNA extraction</i>	121
3.2	RNA QUANTIFICATION	122
3.3	REAL-TIME PCR	123
3.3.1	<i>RNA retrotranscription</i>	124
3.3.2	<i>qPCR</i>	127
3.4	MIRNA PROFILING.....	132
3.4.1	<i>RNA integrity analysis</i>	132
3.4.2	<i>microRNA microarray</i>	133
3.5	PROTEIN EXTRACTION	136
3.6	PROTEIN QUANTIFICATION	137
3.7	SDS-PAGE AND WESTERN BLOT	139
4	PATIENT SAMPLES	144
4.1	RNA EXTRACTION.....	144
4.2	REAL TIME PCR	145
5	BIOINFORMATICS	146

5.1	MICRORNA TARGET PREDICTIONS	146
5.2	MICROARRAY DATA PROCESSING	147
5.2.1	<i>Analysis of expression microarrays</i>	<i>147</i>
5.2.2	<i>Differential expression analysis.....</i>	<i>148</i>
6	STATISTICAL ANALYSIS	149
	RESULTS	151
1	EVALUATION OF METFORMIN AS POSSIBLE TREATMENT FOR TRIPLE NEGATIVE BREAST CANCER	153
1.1	MIR-26A EXPRESSION MODULATES CELL VIABILITY	153
1.2	EFFECT OF MIR-26A ON CELL MIGRATION	157
1.3	EVALUATION OF POTENTIAL MIR-26A TARGETS.....	159
1.4	PHOSPHATASE AND TENSIN HOMOLOG (PTEN) REGULATION BY MIR-26A...	164
1.5	EFFECT OF METFORMIN ON BREAST CANCER CELLS	165
1.6	EFFECT OF METFORMIN THROUGH MIR-26A ON BREAST CANCER CELLS.....	168
2	EPIGENETIC STUDY OF RESISTANCE TO TRASTUZUMAB	171
2.1	MIRNA EXPRESSION ANALYSIS BY MICROARRAY AFFYMETRIX GENECHIP MIRNA	
4.0	171	
2.1.1	<i>Pathway enrichment analysis for breast cancer cell lines ...</i>	<i>178</i>
2.2	VALIDATION OF MIR-23B EXPRESSION BY Q-PCR	181
2.3	STUDY OF MIR-23B EXPRESSION IN PATIENTS	183
2.4	STUDY OF MIR-23B-3P TARGET PTEN.....	187
2.5	VALIDATION OF MIR-146A EXPRESSION BY Q-PCR.....	190
2.6	STUDY OF MIR-146A EXPRESSION IN PATIENTS	191
2.7	STUDY OF MIR-146A-5P IN CELL LINES	195
2.7.1	<i>Cell viability</i>	<i>195</i>

2.7.2	<i>Cell cycle</i>	199
2.7.3	<i>Gene targets</i>	202
2.8	STUDY OF MIR-146A-5P IN EXOSOMES	203
2.8.1	<i>Exosome characterization</i>	203
2.8.2	<i>miR-146a-5p expression</i>	205
2.9	FUNCTIONAL ASSAYS WITH EXOSOMES	207
2.9.1	<i>Cell viability</i>	207
2.9.2	<i>EMT regulation</i>	210
2.9.3	<i>Wound healing assay</i>	212
2.9.4	<i>Angiogenesis assay</i>	213
	DISCUSSION	215
1	METFORMIN	217
2	TRASTUZUMAB	226
	CONCLUSIONS	237
	REFERENCES	243
	ANNEXES	287